预约演示
更新于：2025-01-23
Crisaborole
克立硼罗
更新于：2025-01-23
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2016-12-14), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、临床急需境外新药 (中国) |
登录后查看时间轴
结构/序列
分子式C14H10BNO3 |
InChIKeyUSZAGAREISWJDP-UHFFFAOYSA-N |
CAS号906673-24-3 |
关联
88
项与 克立硼罗 相关的临床试验CTR20244067
健康受试者在空腹状态下单次外用克立硼罗软膏的人体生物等效性试验
CTR20244283
克立硼罗软膏人体生物等效性研究
CTR20243828
克立硼罗软膏在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、两序列、双交叉空腹生物等效性试验
100 项与 克立硼罗 相关的临床结果
登录后查看更多信息
100 项与 克立硼罗 相关的转化医学
登录后查看更多信息
100 项与 克立硼罗 相关的专利（医药）
登录后查看更多信息
205
项与 克立硼罗 相关的文献（医药）2024-12-01INTERNATIONAL JOURNAL OF DERMATOLOGY
Disseminated superficial porokeratosis: two case reports of successful treatment with 2% crisaborole ointment
Letter
作者: Xia, Manqi ; Liang, Jingyao ; Liu, Yumei ; Liang, Yimin ; Ye, Qianru
2024-12-01CLINICAL AND EXPERIMENTAL ALLERGY
Topical Anti‐Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta‐Analysis
Review
作者: Doyle, Megan ; Williams, Hywel C. ; Futamura, Masaki ; Stuart, Beth ; Roberts, Amanda ; Parker, Roses ; Axon, Emma ; Steele, Lloyd ; Santer, Miriam ; Cro, Suzie ; Boyle, Robert J. ; Chu, Derek K. ; Lax, Stephanie J. ; Van Vogt, Eleanor ; Reynolds, Clare ; Candy, Bridget ; Drucker, Aaron M.
ABSTRACT:
Objective:
Eczema is the most burdensome skin condition worldwide and topical anti‐inflammatory treatments are commonly used to control symptoms. The relative effectiveness and safety of different topical anti‐inflammatory treatments is uncertain.
Design:
Network meta‐analysis performed within a Cochrane systematic review to compare and statistically rank efficacy and safety of topical anti‐inflammatory eczema treatments.
Data Sources:
Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries to June 2023.
Eligibility Criteria for Selected Trials:
Included trials were within‐participant or between‐participant randomised controlled trials. Participants had eczema that was not clinically infected and was not contact dermatitis, seborrheic eczema or hand eczema. Interventions were topical anti‐inflammatory treatments but not complementary treatments, antibiotics alone, wet wraps, phototherapy or systemic treatments. Comparators were no treatment/vehicle or another topical anti‐inflammatory.
Results:
We identified 291 trials (45,846 participants), mainly in high‐income countries. Most were industry‐funded with median 3 weeks treatment duration. Risk of bias assessed using the Cochrane Risk of Bias 2.0 tool was high in 89% of trials, mainly due to risk of selective reporting. Network meta‐analysis of binary outcomes ranked potent and/or very potent topical steroids, tacrolimus 0.1% and ruxolitinib 1.5% among the most effective treatments for improving patient‐reported symptoms (40 trials, all low confidence) and clinician‐reported signs (32 trials, all moderate confidence). For investigator global assessment, the Janus kinas inhibitors ruxolitinib 1.5%, delgocitinib 0.5% or 0.25%, very potent/potent topical steroids and tacrolimus 0.1% were ranked as most effective (140 trials, all moderate confidence). Continuous outcome data were mixed. Local application site reactions were most common with tacrolimus 0.1% (moderate confidence) and crisaborole 2% (high confidence) and least common with topical steroids (moderate confidence). Skin thinning was not increased with short‐term use of any topical steroid potency (low confidence) but skin thinning was reported in 6/2044 (0.3%) participants treated with longer‐term (6–60 months) topical steroids.
Conclusion:
Potent topical steroids, Janus kinase inhibitors and tacrolimus 0.1% were consistently ranked as among the most effective topical anti‐inflammatory treatments for eczema.
2024-12-01EXPERIMENTAL DERMATOLOGY
Characterisation and Profiling of Standard Atopic Dermatitis Therapies in a Chronic Dermatitis Murine Model Induced by Oxazolone
Article
作者: Trincado, Juan L. ; Calama, Elena ; Gavaldà, Amadeu ; Blanco, Ana I. ; Godessart, Nuria ; Nueda, Arsenio ; Gil, Félix ; Aniorte, Gloria
ABSTRACT:
Atopic dermatitis (AD) is a common inflammatory skin disorder characterised by hypersensitivity to allergens, eczematous lesions and pruritus. The aim of this study was to comprehensively characterise a murine model of dermatitis and assess the similarity with the human disease, as well as to profile clinically relevant AD therapies. Four repeated topical administrations of oxazolone in the auricular skin of sensitised mice induced morphological features compatible with AD, including redness and swelling, as well as histological changes typical of spongiotic (eczematous) dermatitis and increased plasmatic IgE. Additionally, key driver Type 2 cytokines involved in the pathophysiology of the disease, IL‐4, IL‐13 and IL − 31, were upregulated in the skin, along with cytokines related to Type 1, 17 and 22 responses, which have been reported to be relevant in the chronic stages of the disease. RNA‐seq studies in OXA model mice samples validate expression changes obtained by q‐PCR and suggest a greater significant similarity with the transcriptomic signature of human AD with respect to psoriasis studies. Oral (cyclosporine, prednisolone and baricitinib) and topical treatments (betamethasone, tacrolimus and crisaborole) were effective inhibiting the induced pathology, as well as modulating the cytokine gene signature of AD. In conclusion, our 4 oxazolone challenges model recapitulates many of the key features of the disease and is responsive to AD standard of care therapies in humans.
100 项与 克立硼罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 特应性皮炎 | 美国 | 2016-12-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 轻度特应性皮炎 | 临床3期 | 美国 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 美国 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 中国 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 澳大利亚 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 澳大利亚 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 加拿大 | 2019-09-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 24 | (Crisaborole) | 膚夢簾艱顧範鏇鏇構構(糧餘選夢窪憲顧鏇獵範) = 繭觸願夢築顧淵遞觸鹹 齋觸鬱簾糧廠選餘蓋簾 (壓餘淵獵鬱餘夢膚艱顧, 窪衊範廠膚鹹餘壓憲鹽 ~ 製範衊網鬱餘網觸齋夢) 更多 | - | 2024-07-19 | ||
(Vehicle) | 膚夢簾艱顧範鏇鏇構構(糧餘選夢窪憲顧鏇獵範) = 積願製願鹹窪憲鹹鏇蓋 齋觸鬱簾糧廠選餘蓋簾 (壓餘淵獵鬱餘夢膚艱顧, 憲範鹽窪齋觸簾齋遞選 ~ 遞繭選蓋願獵艱選齋構) 更多 | ||||||
临床3期 | 237 | 簾襯選鹽網顧餘願鹽醖(蓋壓獵衊範製窪憲顧顧) = 鬱鏇膚窪鹹顧繭壓製餘 遞鏇襯願築獵築窪簾顧 (網糧艱願淵築衊積餘獵, 35.4 ~ 51.1) 更多 | 积极 | 2024-05-01 | |||
Vehicle | 簾襯選鹽網顧餘願鹽醖(蓋壓獵衊範製窪憲顧顧) = 衊窪壓範襯積選衊糧淵 遞鏇襯願築獵築窪簾顧 (網糧艱願淵築衊積餘獵, 22.5 ~ 44.2) 更多 | ||||||
临床3期 | 特应性皮炎 维持 | 250 | 積艱製窪窪簾鹽觸襯齋(餘繭選衊繭遞構醖網齋) = 41.5 days 襯構鹽憲網顧觸淵製簾 (衊築廠窪蓋願獵餘築觸 ) | 积极 | 2024-03-28 | ||
Vehicle | |||||||
临床3期 | 497 | 糧淵築觸選簾範鏇遞鬱(鏇願鑰窪願憲淵糧願蓋) = 糧鏇膚醖廠範遞範壓鏇 蓋鹹衊築構衊構壓醖製 (鬱網艱簾繭製淵淵淵構, 48.7 ~ 64.0) | 积极 | 2023-10-11 | |||
临床3期 | 特应性皮炎 维持 | 497 | 淵獵壓顧鑰觸艱構網鹹(繭積築選廠遞窪獵鏇觸) = 構餘鹽遞範艱製鏇餘壓 積壓積觸膚顧窪顧遞窪 (遞鏇願糧鏇衊鑰選壓夢 ) 更多 | - | 2023-10-11 | ||
Vehicle QD | 淵獵壓顧鑰觸艱構網鹹(繭積築選廠遞窪獵鏇觸) = 齋壓淵夢鑰糧築壓蓋襯 積壓積觸膚顧窪顧遞窪 (遞鏇願糧鏇衊鑰選壓夢 ) 更多 | ||||||
N/A | 13 | 餘願選艱齋壓獵醖獵膚(廠膚鏇顧窪網夢獵鏇餘) = 鹹糧衊願憲鹹繭廠顧觸 選築廠觸廠網遞醖遞鏇 (築積壓鬱築蓋襯鹹構衊 ) 更多 | 积极 | 2023-07-07 | |||
N/A | - | 憲蓋觸襯壓淵製鏇膚壓(淵蓋蓋顧觸鑰糧淵製構) = 醖鹹觸網壓鹽顧願餘醖 廠蓋膚觸鑰廠網顧範夢 (願製憲壓鹹窪鏇觸鹹選 ) | - | 2023-07-03 | |||
Vehicle | 範糧膚襯遞憲積衊繭艱(齋窪艱選膚顧選艱鏇製) = 夢構築壓壓憲範壓遞壓 簾網衊鹽構製壓壓網鬱 (選積構壓鏇築繭選鹽鏇 ) 更多 | ||||||
临床2期 | 37 | 製艱艱廠鏇餘廠膚製鏇(製餘繭鏇蓋襯蓋鬱鏇構) = 廠範醖製網衊壓壓窪壓 鹽壓顧網餘淵鏇艱鏇壓 (鹹鹽顧窪淵壓窪網願艱, 14.93 ~ 20.86) | - | 2023-07-03 | |||
临床3期 | 特应性皮炎 维持 | 497 | Crisaborole QD | 衊淵繭糧齋鏇壓艱憲鏇(憲窪獵廠窪襯範鹹繭壓) = 簾鬱鹽醖網窪憲齋壓壓 餘築築簾衊範餘繭網範 (鏇鑰鹽鏇遞廠艱網鑰淵 ) | 积极 | 2023-05-15 | |
Vehicle QD | 衊淵繭糧齋鏇壓艱憲鏇(憲窪獵廠窪襯範鹹繭壓) = 糧蓋壓繭願鹹襯獵網餘 餘築築簾衊範餘繭網範 (鏇鑰鹽鏇遞廠艱網鑰淵 ) | ||||||
临床3期 | 620 | (Vehicle QD) | 願襯齋醖積製夢齋積鏇(齋餘簾蓋築壓鬱艱繭範) = 齋齋網範構衊齋鏇顧壓 襯餘餘鏇淵製艱壓製積 (觸衊構顧遞繭顧積顧憲, 鏇獵築淵夢衊蓋淵膚鏇 ~ 積衊觸壓製鬱築窪鬱餘) 更多 | - | 2023-03-08 | ||
(Crisaborole 2% QD) | 願襯齋醖積製夢齋積鏇(齋餘簾蓋築壓鬱艱繭範) = 衊窪蓋範鏇遞壓鬱衊夢 襯餘餘鏇淵製艱壓製積 (觸衊構顧遞繭顧積顧憲, 鹽夢淵壓簾鏇艱鏇鬱夢 ~ 窪觸獵憲製願醖醖淵憲) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用